Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020

By sjmartinez • October 28, 2022

Qian MF, Betancourt NJ, Pineda A, Maloney NJ, Nguyen KA, Reddy SA, Hall ET, Swetter SM, Zaba LC. Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020. Oncologist. 2022 Oct 27:oyac219. doi: 10.1093/oncolo/oyac219. Epub ahead of print. PMID: 36302223.

Tags: administrative claims, Dermatology, healthcare, Healthcare cost, immune checkpoint inhibitors, melanoma, molecular targeted therapy, Publications

Cutaneous Adverse Reactions to IL-17 and IL-23 Inhibitors: A Clinical Review of Reaction Patterns

Park I, Bayrouti A, MacIntyre D, Le V, Nguyen KB. Cutaneous Adverse Reactions to IL-17 and IL-23 Inhibitors: A Clinical Review of Reaction Patterns. Dermatol[...]

Closing the Gap: The Ethics of Non-Physician Delegation in Mohs Reconstruction

Li R, Ramirez Y, Stone L, Klufas T, Zhou AE, Tucci C, Beynet DP, Lo Sicco K, Grant-Kels JM. Closing the Gap: The Ethics of[...]

2026 Ebola Virus Disease Outbreak: What Dermatologists Should Know

Rosenbach M, Boghosian T, Granovsky R, Rimmer S, Chiu Y, Elewski BE, Rosmarin D, Said J, Trinidad JC, Zheng L, Goh C; American Academy of[...]